메뉴 건너뛰기




Volumn 49, Issue 15, 2016, Pages 1202-1204

Investigation into the interference of the monoclonal antibody daratumumab on the free light chain assay

Author keywords

Anti CD38; Daratumumab; Free light chains; Monoclonal antibodies; Myeloma

Indexed keywords

DARATUMUMAB; IMMUNOGLOBULIN A KAPPA; IMMUNOGLOBULIN A LAMBDA; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; IMMUNOGLOBULIN M; IMMUNOGLOBULIN M KAPPA; UNCLASSIFIED DRUG; IMMUNOGLOBULIN LIGHT CHAIN; MONOCLONAL ANTIBODY;

EID: 84992034885     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2016.07.016     Document Type: Article
Times cited : (22)

References (15)
  • 1
    • 79956001465 scopus 로고    scopus 로고
    • Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3
    • [1] Dimopoulos, M., Kyle, R., Fermand, J.P., et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 117:18 (2011), 4701–4705.
    • (2011) Blood , vol.117 , Issue.18 , pp. 4701-4705
    • Dimopoulos, M.1    Kyle, R.2    Fermand, J.P.3
  • 2
    • 60149096306 scopus 로고    scopus 로고
    • International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
    • [2] Dispenzieri, A., Kyle, R., Merlini, G., et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 23:2 (2009), 215–224.
    • (2009) Leukemia , vol.23 , Issue.2 , pp. 215-224
    • Dispenzieri, A.1    Kyle, R.2    Merlini, G.3
  • 3
    • 38349136782 scopus 로고    scopus 로고
    • Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma
    • [3] Dispenzieri, A., Kyle, R.A., Katzmann, J.A., et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 111:2 (2008), 785–789.
    • (2008) Blood , vol.111 , Issue.2 , pp. 785-789
    • Dispenzieri, A.1    Kyle, R.A.2    Katzmann, J.A.3
  • 4
    • 84943583461 scopus 로고    scopus 로고
    • Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy
    • [4] Alhaj Moustafa, M., Rajkumar, S.V., Dispenzieri, A., et al. Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy. Leukemia 29:10 (2015), 2033–2038.
    • (2015) Leukemia , vol.29 , Issue.10 , pp. 2033-2038
    • Alhaj Moustafa, M.1    Rajkumar, S.V.2    Dispenzieri, A.3
  • 5
    • 58249097191 scopus 로고    scopus 로고
    • Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
    • [5] Kyle, R.A., Rajkumar, S.V., Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 23:1 (2009), 3–9.
    • (2009) Leukemia , vol.23 , Issue.1 , pp. 3-9
    • Kyle, R.A.1    Rajkumar, S.V.2
  • 6
    • 79955977910 scopus 로고    scopus 로고
    • Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
    • [6] Rajkumar, S.V., Harousseau, J.L., Durie, B., et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 117:18 (2011), 4691–4695.
    • (2011) Blood , vol.117 , Issue.18 , pp. 4691-4695
    • Rajkumar, S.V.1    Harousseau, J.L.2    Durie, B.3
  • 7
    • 34249696500 scopus 로고    scopus 로고
    • Detection by immunofixation of M proteins in hypogammaglobulinemic patients with normal serum protein electrophoresis results
    • [7] Lakshminarayanan, R., Li, Y., Janatpour, K., Beckett, L., Jialal, I., Detection by immunofixation of M proteins in hypogammaglobulinemic patients with normal serum protein electrophoresis results. Am. J. Clin. Pathol. 127:5 (2007), 746–751.
    • (2007) Am. J. Clin. Pathol. , vol.127 , Issue.5 , pp. 746-751
    • Lakshminarayanan, R.1    Li, Y.2    Janatpour, K.3    Beckett, L.4    Jialal, I.5
  • 8
    • 84942437054 scopus 로고    scopus 로고
    • Monoclonal antibodies in multiple myeloma come of age
    • [8] Raje, N., Longo, D.L., Monoclonal antibodies in multiple myeloma come of age. N. Engl. J. Med. 373:13 (2015), 1264–1266.
    • (2015) N. Engl. J. Med. , vol.373 , Issue.13 , pp. 1264-1266
    • Raje, N.1    Longo, D.L.2
  • 9
    • 84927177719 scopus 로고    scopus 로고
    • Current treatment landscape for relapsed and/or refractory multiple myeloma
    • [9] Dimopoulos, M.A., Richardson, P.G., Moreau, P., Anderson, K.C., Current treatment landscape for relapsed and/or refractory multiple myeloma. Nat. Rev. Clin. Oncol. 12:1 (2015), 42–54.
    • (2015) Nat. Rev. Clin. Oncol. , vol.12 , Issue.1 , pp. 42-54
    • Dimopoulos, M.A.1    Richardson, P.G.2    Moreau, P.3    Anderson, K.C.4
  • 10
    • 84942436321 scopus 로고    scopus 로고
    • Targeting CD38 with daratumumab monotherapy in multiple myeloma
    • [10] Lokhorst, H.M., Plesner, T., Laubach, J.P., et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N. Engl. J. Med. 373:13 (2015), 1207–1219.
    • (2015) N. Engl. J. Med. , vol.373 , Issue.13 , pp. 1207-1219
    • Lokhorst, H.M.1    Plesner, T.2    Laubach, J.P.3
  • 11
    • 84959423326 scopus 로고    scopus 로고
    • Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma
    • [11] van de Donk, N.W., Moreau, P., Plesner, T., et al. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood 127:6 (2016), 681–695.
    • (2016) Blood , vol.127 , Issue.6 , pp. 681-695
    • van de Donk, N.W.1    Moreau, P.2    Plesner, T.3
  • 12
    • 84953325096 scopus 로고    scopus 로고
    • Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
    • [12] Lonial, S., Weiss, B.M., Usmani, S.Z., et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 387:10027 (2016), 1551–1560.
    • (2016) Lancet , vol.387 , Issue.10027 , pp. 1551-1560
    • Lonial, S.1    Weiss, B.M.2    Usmani, S.Z.3
  • 13
    • 84953234682 scopus 로고    scopus 로고
    • Daratumumab in multiple myeloma
    • [13] Rajkumar, S.V., Daratumumab in multiple myeloma. Lancet, 2016.
    • (2016) Lancet
    • Rajkumar, S.V.1
  • 14
    • 84969776462 scopus 로고    scopus 로고
    • Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA)
    • [14] van de Donk, N.W., Otten, H.G., El Haddad, O., et al. Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA). Clin. Chem. Lab. Med., 2016.
    • (2016) Clin. Chem. Lab. Med.
    • van de Donk, N.W.1    Otten, H.G.2    El Haddad, O.3
  • 15
    • 84969835048 scopus 로고    scopus 로고
    • Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference
    • [15] McCudden, C., Axel, A.E., Slaets, D., et al. Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference. Clin. Chem. Lab. Med., 2016.
    • (2016) Clin. Chem. Lab. Med.
    • McCudden, C.1    Axel, A.E.2    Slaets, D.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.